about
HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphomaA phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphomaCyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy.
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Novel therapeutic targets in mantle cell lymphoma.
@en
type
label
Novel therapeutic targets in mantle cell lymphoma.
@en
prefLabel
Novel therapeutic targets in mantle cell lymphoma.
@en
P2860
P1476
Novel therapeutic targets in mantle cell lymphoma.
@en
P2093
John P Leonard
Peter Martin
P2860
P304
P356
10.1517/14728222.11.7.929
P407
P577
2007-07-01T00:00:00Z